Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Week 48 Efficacy Outcomes by Baseline Demographics in the Phase 2/3 PHOTON Trial

被引：0
|
作者：
Ghorayeb, Ghassan [1 ]
机构：
[1] West Virginia Univ, Eye Inst, Morgantown, WV USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2023年 / 64卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
2707
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Intraocular pressure outcomes with intravitreal injection of aflibercept 8 mg and 2 mg in patients with diabetic macular edema through Week 48 of the phase 2/3 PHOTON trial
    Barakat, Mark Rami
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [2] Aflibercept 8 mg for Diabetic Macular Edema: 48-Week Results From the Phase 2/3 PHOTON Trial
    Do, Diana
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [3] Infographic: Efficacy and safety of high-dose intravitreal aflibercept 8 mg in patients with diabetic macular oedema: Week 48 results from the phase 2/3 PHOTON trial
    Sivaprasad, Sobha
    Reed, Kimberly
    Morgan-Warren, Peter
    Leal, Sergio
    Berliner, Alyson
    EYE, 2025,
  • [4] Intravitreal Ziv-Aflibercept for Diabetic Macular Edema: 48-Week Outcomes
    de Andrade, Gabriel Costa
    de Oliveira Dias, Joao Rafael
    Maia, Andre
    Farah, Michel Eid
    Meyer, Carsten H.
    Rodrigues, Eduardo Buchele
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2018, 49 (04): : 245 - 250
  • [5] Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial
    Brown, David M.
    Boyer, David S.
    Do, Diana, V
    Wykoff, Charles C.
    Sakamoto, Taiji
    Win, Peter
    Joshi, Sunir
    Salehi-Had, Hani
    Seres, Andras
    Berliner, Alyson J.
    Leal, Sergio
    Vitti, Robert
    Chu, Karen W.
    Reed, Kimberly
    Rao, Rohini
    Cheng, Yenchieh
    Sun, Wei
    Voronca, Delia
    Bhore, Rafia
    Schmidt-Ott, Ursula
    Schmelter, Thomas
    Schulze, Andrea
    Zhang, Xin
    Hirshberg, Boaz
    Yancopoulos, George
    Sivaprasad, Sobha
    LANCET, 2024, 403 (10432): : 1153 - 1163
  • [6] Intravitreal Nesvacumab plus Aflibercept in Diabetic Macular Edema: The Phase 2 RUBY Trial
    Boyer, David S.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [7] INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA Phase 2 RUBY Randomized Trial
    Brown, David M.
    Boyer, David S.
    Csaky, Karl
    Vitti, Robert
    Perlee, Lorah
    Chu, Karen W.
    Asmus, Friedrich
    Leal, Sergio
    Zeitz, Oliver
    Cheng, Yenchieh
    Schmelter, Thomas
    Heier, Jeffrey S.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2022, 42 (06): : 1111 - 1120
  • [8] EFFICACY AND SAFETY OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOCUSING ON PATIENTS WITH DIABETIC MACULAR EDEMA FROM JAPAN
    Terasaki, Hiroko
    Shiraki, Kunihiko
    Ohji, Masahito
    Metzig, Carola
    Schmelter, Thomas
    Zeitz, Oliver
    Sowade, Olaf
    Kobayashi, Masato
    Vitti, Robert
    Berliner, Alyson
    Shiraga, Fumio
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2019, 39 (05): : 938 - 947
  • [9] Week 48 outcomes in aflibercept 8 mg-and 2 mg-treated patients by prior DME treatment status: a subgroup analysis of the phase 2/3 PHOTON trial
    Mehta, Nitish
    Mehta, Nitish
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [10] Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the Phase 3 PULSAR trial
    Spitzer, Martin Stephan
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
12345